Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: A retrospective analysis of data from a randomised controlled trial

BMC Ophthalmology

Volumn 14, Issue 1, 2014, Pages

  O'Day, Roderick F ^a   Barthelmes, Daniel ^a   Zhu, Meidong ^a   Wong, Tien Y ^b,c   McAllister, Ian L ^d   Arnold, Jennifer J ^e   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Marsden Eye Specialists   (Australia)

Author keywords

Adverse events; Diabetic macular oedema; Efficacy; Intraocular pressure rise; Intravitreal triamcinolone; Vision improvement

Indexed keywords

GLUCOCORTICOID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; TRIAMCINOLONE ACETONIDE;

AGED; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY;

AGED; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84929132139     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-14-123     Document Type: Article

References (30)

1. Kohner E: Diabetic retinopathy. Clin Endocrinol Metab 1977, 6:345-375.
2. Giuliari GP: Diabetic retinopathy: current and new treatment options. Curr Diabetes Rev 2012, 8:32-41.
3. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M: Intravitreal becavizumab (Avastin) versus ranibuzumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011, 95:308-317.
4. Quaggin SE: Turning a blind eye to anti-VEGF toxicities. J Clin Invest 2012, [Epub ahead of print].
5. van Wijngararden P, Coster DJ, Williams KA: Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005, 293:1509-1513.
6. Sutter FK, Simpson JM, Gillies MC: Intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004, 111:2044-2049.
7. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular oedema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006, 113:1533-1538.
8. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, Sutter F: Five-year results of a randomized clinical trial with open label extension of intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2009, 116:2182-2187.
9. Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, Wong TY: Pretreatment with intravitreal triamcinolone before laser for diabetic macular oedema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci 2010, 51:2322-2328.
10. Jonas JB, Kamppeter BA, Harder B, Vosmmerbaeumer U, Sauder G, Spandau UH: Intravitreal triamcinolone acetonide for diabetic macular oedema: a prospective, randomized study. J Ocul Phamacol Ther 2006, 22:200-207.
11. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A: Intravitreal triamcinolone acetonide for diabetic diffuse macular oedema: Preliminary results of a prospective controlled trial. Ophthalmology 2004, 111:218-224.
12. Diabetic Retinopathy Clinical Research Network Ophthalmology: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular oedema. Ophthalmology 2008, 115:1447-1459.
13. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB: Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004, 122:336-340.
14. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ: Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye (Lond) 2007, 21:317-320.
15. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson J: Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005, 112:139-143.
16. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005, 112:593-598.
17. Chae JB, Joe SG, Yang SJ, Lee JY, Kim J-G, Yoon TH: An increase in intraocular pressure after intravitreal steroid injection facilitates reduce of macular edema. Eye (Lond) 2012, 26:479-480.
18. Sonmez K, Ozturk F: Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation. Int J Ophthalmol 2012, 5:719-725.
19. Jonas J, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Opthalmol 2003, 87:24-27.
20. Hernandez MR, Wenk EJ, Weinstein BI, Abumohor P, Podos SM, Dunn MW, Southren AL: Glucocorticoid target cells in human outflow pathway: autopsy and surgical specimens. Invest Ophthalmol Vis Sci 1983, 24:1612-1616.
21. Weinreb RN, Bloom E, Baxter JD, Alvarado J, Lan N, O'Donnell J, Polansky JR: Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci 1981, 21:403-407.
22. Vijayasekaran S, McAllister IL, Morgan WH, Mendis KR, McMenamin PG, Cringle SJ, Yu DY: Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2011, 249:215-222.
23. Becker B, Mills DW: Corticosteroids and intraocular pressure. Arch Ophthalmol 1963, 70:500-507.
24. Johnson DH, Bradley JM, Ascott TS: The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in the perfusion organ culture. Invest Ophthalmol Vis Sci 1990, 31:2568-2571.
25. Larsson J, Zhu M, Sutter F, Gillies MC: Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 2005, 139:802-806.
26. Tretiach M, Madigan MC, Wen L, Gillies MC: Effect of muller cell co-culture on in vitro permeability of bovine retinal vascular endothelium in normoxic and hypoxic conditions. Neurosci Lett 2005, 378:160-165.
27. Wenzel A, Grimm C, Seeliger MW, Jaissle G, Hafezi F, Kretschmer R, Zrenner E, Remé CE: Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 2001, 42:1653-1659.
28. Edelman JL: Differentiating intraocular glucocorticoids. Ophthalmologica 2010, 224:25-30.
29. Shin HJ, Lee SH, Chung H, Kim HC: Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2012, 250:61-70.
30. James ER, Robertson L, Ehlert E, Fitzgerald P, Droin N, Green DR: Presence of a transcriptionally active glucocorticoid receptor α in lens epithelial cells. Invest Ophthalmol Vis Sci 2003, 44:5269-5276.